Overview
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
Description
PRIMARY OBJECTIVE:
I. To collect biospecimens from 1) patients who developed chemotherapy related cardiac toxicity (CRCT) and 2) patients who are at a high risk for developing CRCT identified prior to the onset of therapy.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and have their medical records reviewed on study.
Eligibility
Inclusion Criteria:
- * 18 years of age or older
- Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
- Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment OR completed chemotherapy with no cardiotoxicity at least two years post treatment OR Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
- An understanding of the protocol and its requirements, risks, and discomforts
- The ability and willingness to sign an informed consent
Exclusion Criteria:
- * Inability on the part of the patient to understand the informed consent or be compliant with the protocol